ABCL logo

AbCellera Biologics Inc. Stock Price

NasdaqGS:ABCL Community·US$1.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 81 Fair Values set on narratives written by author
Create a narrative

ABCL Share Price Performance

US$5.53
3.01 (119.44%)
67.5% undervalued intrinsic discount
US$17.00
Fair Value
US$5.53
3.01 (119.44%)
67.5% undervalued intrinsic discount
US$17.00
Fair Value
Price US$5.53
AnalystHighTarget US$17.00
AnalystConsensusTarget US$9.22
AnalystLowTarget US$5.00

ABCL Community Narratives

AnalystHighTarget·
Fair Value US$17 67.5% undervalued intrinsic discount

AI Integration And Internal Pipeline Will Accelerate Biologics Growth

1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystConsensusTarget·
Fair Value US$9.33 40.8% undervalued intrinsic discount

Phase I Trials And Manufacturing Will Unlock Pipeline Potential

0users have liked this narrative
0users have commented on this narrative
46users have followed this narrative
AnalystLowTarget·
Fair Value US$5 10.6% overvalued intrinsic discount

Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent ABCL News & Updates

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 06
User avatar

Phase I Trials And Manufacturing Will Unlock Pipeline Potential

Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.

Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates

May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates

AbCellera Biologics Inc. Key Details

US$32.9m

Revenue

US$168.8m

Cost of Revenue

-US$135.9m

Gross Profit

US$29.8m

Other Expenses

-US$165.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
-0.55
Gross Margin
-413.31%
Net Profit Margin
-503.91%
Debt/Equity Ratio
0%

AbCellera Biologics Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet and good value.

1 Risk
2 Rewards
View Full Analysis

About ABCL

Founded
2012
Employees
596
CEO
Carl Hansen
WebsiteView website
www.abcellera.com

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

Canadian Market Performance

  • 7 Days: -1.5%
  • 3 Months: 8.0%
  • 1 Year: 18.8%
  • Year to Date: 18.4%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 2.0% in the Financials sector. As for the longer term, the market has actually risen by 19% in the last year. Earnings are forecast to grow by 11% annually. Market details ›